CEL-SCI Corporation (CVM): Price-to-Revenue Ratio

CEL-SCI Corporation's critical dependence on external manufacturing and testing contractors defines its operational risk. The GURU.Markets portal features a P/S ratio chart, where represents the latest metric reading. CEL-SCI Corporation is developing the Multikine system for the preliminary stimulation of patient immunity. Meanwhile, the business's environmental profile is limited to standard bio-waste disposal in accordance with government regulations.

The P/S ratio is calculated as the ratio of CEL-SCI Corporation (CVM) market capitalization to its total annual revenue. This metric determines how much investors are willing to pay for every dollar of sales, assessing the efficiency of asset monetization. For the biotechnology sector, characterized by volatile income and a dependence on grants, this indicator becomes a key marker of speculative expectations. Analyzing the price-to-sales ratio helps identify critical points of business overvaluation.